59 related articles for article (PubMed ID: 30535536)
1. Dasatinib and Trametinib Promote Anti-Tumor Metabolic Activity.
Bolf EL; Beadnell TC; Rose MM; D'Alessandro A; Nemkov T; Hansen KC; Schweppe RE
Cells; 2023 May; 12(10):. PubMed ID: 37408209
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib Is Preferentially Active in the Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma.
Cann ML; Herring LE; Haar LL; Gilbert TSK; Goldfarb D; Richards KL; Graves LM; Lawrence DS
J Proteome Res; 2019 Jan; 18(1):522-534. PubMed ID: 30540191
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).
Boku N; Ryu MH; Kato K; Chung HC; Minashi K; Lee KW; Cho H; Kang WK; Komatsu Y; Tsuda M; Yamaguchi K; Hara H; Fumita S; Azuma M; Chen LT; Kang YK
Ann Oncol; 2019 Feb; 30(2):250-258. PubMed ID: 30566590
[TBL] [Abstract][Full Text] [Related]
4. National patterns of care and cancer-specific outcomes of adjuvant treatment in patients with serous and clear cell endometrial carcinoma.
Xiang M; English DP; Kidd EA
Gynecol Oncol; 2019 Mar; 152(3):599-604. PubMed ID: 30551884
[TBL] [Abstract][Full Text] [Related]
5. Endometrial Carcinoma, Grossing and Processing Issues: Recommendations of the International Society of Gynecologic Pathologists.
Malpica A; Euscher ED; Hecht JL; Ali-Fehmi R; Quick CM; Singh N; Horn LC; Alvarado-Cabrero I; Matias-Guiu X; Hirschowitz L; Duggan M; Ordi J; Parkash V; Mikami Y; Ruhul Quddus M; Zaino R; Staebler A; Zaloudek C; McCluggage WG; Oliva E
Int J Gynecol Pathol; 2019 Jan; 38 Suppl 1(Iss 1 Suppl 1):S9-S24. PubMed ID: 30550481
[TBL] [Abstract][Full Text] [Related]
6. A long noncoding RNAs signature to improve survival prediction in endometrioid endometrial cancer.
Xu Q; Yang Q; Zhou Y; Yang B; Jiang R; Ai Z; Teng Y
J Cell Biochem; 2019 May; 120(5):8300-8310. PubMed ID: 30548294
[TBL] [Abstract][Full Text] [Related]
7. Class I Phosphoinositide 3-Kinase
Mazloumi Gavgani F; Smith Arnesen V; Jacobsen RG; Krakstad C; Hoivik EA; Lewis AE
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544563
[TBL] [Abstract][Full Text] [Related]
8. The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer.
Hsu PC; Yang CT; Jablons DM; You L
Biomedicines; 2018 Dec; 6(4):. PubMed ID: 30544524
[TBL] [Abstract][Full Text] [Related]
9. Dietary intake of nutrients involved in folate-mediated one-carbon metabolism and risk for endometrial cancer.
Lu J; Trabert B; Liao LM; Pfeiffer RM; Michels KA
Int J Epidemiol; 2019 Apr; 48(2):474-488. PubMed ID: 30544261
[TBL] [Abstract][Full Text] [Related]
10. Management of endometrial, ovarian and cervical cancer in the elderly: current approach to a challenging condition.
Vitale SG; Capriglione S; Zito G; Lopez S; Gulino FA; Di Guardo F; Vitagliano A; Noventa M; La Rosa VL; Sapia F; Valenti G; Rapisarda AMC; Peterlunger I; Rossetti D; Laganà AS
Arch Gynecol Obstet; 2019 Feb; 299(2):299-315. PubMed ID: 30542793
[TBL] [Abstract][Full Text] [Related]
11. A Matched Analysis on the Prognostic Impact of Race on Survival Endpoints of Women with Early-Stage Endometrial Cancer.
Feldman A; Chaugle S; Burmeister C; Munkarah A; Elshaikh MA
Gynecol Obstet Invest; 2019; 84(3):283-289. PubMed ID: 30540995
[TBL] [Abstract][Full Text] [Related]
12. Expression of programmed death-ligand 1 and hypoxia-inducible factor-1α proteins in endometrial carcinoma.
Tawadros AIF; Khalafalla MMM
J Cancer Res Ther; 2018 Dec; 14(Supplement):S1063-S1069. PubMed ID: 30539847
[TBL] [Abstract][Full Text] [Related]
13. Modelled Economic Evaluation of Nivolumab for the Treatment of Second-Line Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer in Australia Using Both Partition Survival and Markov Models.
Gao L; Li SC
Appl Health Econ Health Policy; 2019 Jun; 17(3):371-380. PubMed ID: 30535675
[TBL] [Abstract][Full Text] [Related]
14. Role of c-Src in Carcinogenesis and Drug Resistance.
Raji L; Tetteh A; Amin ARMR
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201459
[TBL] [Abstract][Full Text] [Related]
15. Attitudes and barriers to participation in window-of-opportunity trials reported by White and Asian/Asian British ethnicity patients who have undergone treatment for endometrial cancer.
Mandane B; Amirthanayagam A; Patel N; Darko N; Moss EL
Trials; 2023 Nov; 24(1):754. PubMed ID: 38007461
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib: a potential tyrosine kinase inhibitor to fight against multiple cancer malignancies.
Fauziya ; Gupta A; Nadaf A; Ahmad S; Hasan N; Imran M; Sahebkar A; Jain GK; Kesharwani P; Ahmad FJ
Med Oncol; 2023 May; 40(6):173. PubMed ID: 37165283
[TBL] [Abstract][Full Text] [Related]
17. RASSF1C oncogene elicits amoeboid invasion, cancer stemness, and extracellular vesicle release via a SRC/Rho axis.
Tognoli ML; Vlahov N; Steenbeek S; Grawenda AM; Eyres M; Cano-Rodriguez D; Scrace S; Kartsonaki C; von Kriegsheim A; Willms E; Wood MJ; Rots MG; van Rheenen J; O'Neill E; Pankova D
EMBO J; 2021 Oct; 40(20):e107680. PubMed ID: 34532864
[TBL] [Abstract][Full Text] [Related]
18. Small-Molecule Inhibitors (SMIs) as an Effective Therapeutic Strategy for Endometrial Cancer.
Megino-Luque C; Moiola CP; Molins-Escuder C; López-Gil C; Gil-Moreno A; Matias-Guiu X; Colas E; Eritja N
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32987790
[TBL] [Abstract][Full Text] [Related]
19. A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer.
Duska LR; Petroni GR; Lothamer H; Faust W; Beumer JH; Christner SM; Mills AM; Fracasso PM; Parsons SJ
Cancer Chemother Pharmacol; 2019 Mar; 83(3):473-482. PubMed ID: 30535536
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
